Yahoo España Búsqueda web

Search results

1. pipelinereview.com › intellia-therapeutics-announces-positive-long-term-dataIntellia Therapeutics Announces Positive Long-Term Data from...

   pipelinereview.com › intellia-therapeutics-announces-positive-long-term-data

   • En caché

   Hace 14 horas · Intellia’s ongoing Phase 1/2 study is evaluating the safety and activity of NTLA-2002 in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1/2 is an international, open-label study designed to identify a dose level of NTLA-2002 for further evaluation in a Phase 3 study. Enrollment of the Phase 1/2 is complete.

2. www.thenational.scot › 24361373Is motor neurone disease hereditary? See what might cause it

   www.thenational.scot › 24361373

   • En caché

   Hace 14 horas · MND Association says inherited MND affects up to 1 in 10 people with MND, where there is a family history of the disease. However, it states: “If you have a family history of MND, it does not mean you will definitely get the condition, as other risk factors are usually needed for MND to begin. “You may also hear inherited MND being called ...

3. www.openpr.com › news › 3523512Global Hereditary Angioedema Market Set to Experience 7.5% CAGR

   www.openpr.com › news › 3523512

   3 de jun. de 2024 · Global Hereditary Angioedema Market Set to Experience 7.5% CAGR Growth from 2022 to 2030 06-03-2024 03:23 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: Dataintelo

4. Vídeos

   • 

     2:07

     youtube.com

     Hereditary | Official Trailer HD | A24

     30 ene 2018

     30M vistas

   • 

     2:23

     youtube.com

     HEREDITARY - Trailer SUBTITULADO 2018

     30 ene 2018

     1.3M vistas

   • 

     2:07

     youtube.com

     "Hereditary" - Trailer en español

     27 mar 2018

     49 vistas

   Ver todo

5. markets.ft.com › data › announceCompany Announcements - Financial Times

   markets.ft.com › data › announce

   • En caché

   Hace 14 horas · Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers Rashmi Jain, Consultant in Clinical Immunology, Oxford University Hospital Trust, ... Results from this analysis highlight that survey respondents with HAE who treat their attacks early (<1 hour) ...

6. www.mdpi.com › 1424/8220/24-11 › 3613Sensors | Free Full-Text | Optimizing Rare Disease Gait ... -...

   www.mdpi.com › 1424/8220/24-11 › 3613

   • En caché

   Hace 14 horas · AMA Style. Trabassi D, Castiglia SF, Bini F, Marinozzi F, Ajoudani A, Lorenzini M, Chini G, Varrecchia T, Ranavolo A, De Icco R, et al. Optimizing Rare Disease Gait Classification through Data Balancing and Generative AI: Insights from Hereditary Cerebellar Ataxia.

7. www.stocktitan.net › news › KALVKalVista Pharmaceuticals Presents Data on Persisting Unmet Needs...

   www.stocktitan.net › news › KALV

   • En caché

   Hace 14 horas · Patients treating HAE attacks early recover faster (1.4 hours vs. 2.9 hours) and achieve full recovery sooner (1.3 days vs. 1.9 days). Oral on-demand treatments preferred by 95.1% of patients, indicating high market potential. Phase 3 KONFIDENT results support the efficacy of oral sebetralstat, promising to shift treatment paradigms.

8. finance.yahoo.com › news › kalvista-pharmaceuticals-presents-data-persistingKalVista Pharmaceuticals Presents Data on Persisting Unmet Needs...

   finance.yahoo.com › news › kalvista-pharmaceuticals-presents-data-persisting

   • En caché

   Hace 14 horas · CAMBRIDGE, Mass. & SALISBURY, England, June 03, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented real-world data from US patient surveys that assessed the ...